ClinicalTrials.gg
CompletedNCT02912845Updated Sep 5, 2021

Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies

A Phase 3 interventional study of KamRAB - HRIG in Rabies, sponsored by Kamada, Ltd.. Completed at 1 site in United States. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-09-05.

Sponsored by Kamada, Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2019, 7 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Rabies with a site in United States — none open to participants now, none under way, none of them phase 3. Rabies · United States.

Enrollment
16th of 17
30 · median 130
Started
2016
with 3 others
Phase 3
Only one
of the 19
Registered
10th of 19
by date
Lead sponsor
2 of 19
Kamada, Ltd.

Among the 19 studies in Rabies with a site in United States, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2016, is the only one in phase 3, and was the 10th registered.

Rabies

115 studies on the registry are indexed under Rabies; 12 are open to participants now.

Browse Rabies studies →

Open to participants now

None of the 19 studies in Rabies with a site in United States is open now. The open studies under Rabies, anywhere →

Who these studies take

Of the 2 Rabies studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Rabies with a site in United States as a file.
02

Study summary

The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to \<17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).

03

Conditions studied

  • Rabies

Browse trials for

04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy children (male and female) ages 0 months to \<17 years.
  • Have been exposed or possibly exposed to rabies.
  • Are indicated to receive post-exposure prophylaxis (PEP) against rabies infection.
  • Have documented from the child's parent(s) or legal guardian(s) and assent from the child if appropriate.

Exclusion criteria

Exclusion Criteria:

  • History of previous administration of rabies vaccine or human rabies immune globulin (HRIG)
  • Rabies exposure or possible rabies exposure more than seven days prior to initiation of PEP, or timing of exposure unknown
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    20 IU/kg KamRAB + Active Anti-Rabies Vaccine

    Drug: KamRAB - HRIG

Interventions

  • DrugKamRAB - HRIG

    wound infiltration or IM injection

06

What researchers measure

Primary outcomes

  1. Frequency and severity of local and systemic adverse events occurring within 14 days of KamRAB treatment

    Time frame: Within 14 days from treatment

  2. Frequency and severity of local and systemic SAEs occurring within 84 days of KamRAB treatment

    Time frame: Within 84 days of treatment

07

Study locations

1 site
  • ACH
    Little Rock, Arkansas 12345, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Nov 2019, 39 months.

Of 22 phase 3 interventional studies under Rabies, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2016
First posted
Sep 23, 2016
StartActual
Aug 1, 2016
Primary completionActual
Nov 13, 2019
CompletionActual
Nov 13, 2019
Last update
Sep 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02912845
Lead sponsor
Kamada, Ltd.
Collaborators
Kedrion S.p.A.
Responsible party
Sponsor
First posted
Sep 23, 2016
Start date
Aug 1, 2016
Primary completion
Nov 13, 2019
Completion
Nov 13, 2019
Last update
Sep 5, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion